Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: Tissue microarray analysis of immunohistochemical scores with clinicopathological parameters

W. C. Tsai, Y. C. Chao, W. H. Lee, A. Chen, L. F. Sheu, J. S. Jin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Aims: To examine the expression of extracellular matrix metalloprotease inducer (EMMPRIN) and matriptase in hepatocellular carcinoma (HCC) and to correlate this with tumour progression. Methods and results: Immunohistochemical analysis of EMMPRIN and matriptase was performed on tissue microarrays of 122 cases of HCC with various histological grades and/or clinical parameters. The expression of EMMPRIN and matriptase was undetectable in normal liver parenchyma of all eight control cases. However, among the 122 HCC cases, EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm. The average immunostaining scores of EMMPRIN were 88 for grade I HCC, 195 for grade II HCC and 293 for grade III HCC. Of 85 HCC cases in 122 with detailed clinical TNM stages, the average immunostaining scores of EMMPRIN were 75 for stage T1, 177 for stage T2, 260 for stage T3 and 313 for stage T4 cases of HCC. In addition, the average immunostaining scores of matriptase were 84 for grade I HCC, 187 for grade II HCC, 302 for grade III HCC, and 72 for stage T1, 181 for stage T2, 224 for stage T3 and 284 for stage T4 cases of HCC. More advanced M and N stages of HCC were associated with higher intensity, greater percentages of tumour staining and immunostaining scores of EMMPRIN and matriptase. Higher EMMPRIN and matriptase immunostaining scores in HCCs also correlated significantly with tumour grading and TNM stages. Conclusions: Our findings demonstrate for the first time that EMMPRIN and matriptase are overexpressed in HCC. These may be novel biomarkers for the diagnosis and treatment of HCC.

Original languageEnglish
Pages (from-to)388-395
Number of pages8
JournalHistopathology
Volume49
Issue number4
DOIs
Publication statusPublished - Oct 2006
Externally publishedYes

Fingerprint

Tissue Array Analysis
Metalloproteases
Extracellular Matrix
Hepatocellular Carcinoma
matriptase
Neoplasm Grading

Keywords

  • CD147
  • EMMPRIN
  • Hepatocellular carcinoma
  • Matriptase
  • Serine proteinase

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma : Tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. / Tsai, W. C.; Chao, Y. C.; Lee, W. H.; Chen, A.; Sheu, L. F.; Jin, J. S.

In: Histopathology, Vol. 49, No. 4, 10.2006, p. 388-395.

Research output: Contribution to journalArticle

@article{4092f7b6944c44aab336e0c0b6d3624b,
title = "Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: Tissue microarray analysis of immunohistochemical scores with clinicopathological parameters",
abstract = "Aims: To examine the expression of extracellular matrix metalloprotease inducer (EMMPRIN) and matriptase in hepatocellular carcinoma (HCC) and to correlate this with tumour progression. Methods and results: Immunohistochemical analysis of EMMPRIN and matriptase was performed on tissue microarrays of 122 cases of HCC with various histological grades and/or clinical parameters. The expression of EMMPRIN and matriptase was undetectable in normal liver parenchyma of all eight control cases. However, among the 122 HCC cases, EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm. The average immunostaining scores of EMMPRIN were 88 for grade I HCC, 195 for grade II HCC and 293 for grade III HCC. Of 85 HCC cases in 122 with detailed clinical TNM stages, the average immunostaining scores of EMMPRIN were 75 for stage T1, 177 for stage T2, 260 for stage T3 and 313 for stage T4 cases of HCC. In addition, the average immunostaining scores of matriptase were 84 for grade I HCC, 187 for grade II HCC, 302 for grade III HCC, and 72 for stage T1, 181 for stage T2, 224 for stage T3 and 284 for stage T4 cases of HCC. More advanced M and N stages of HCC were associated with higher intensity, greater percentages of tumour staining and immunostaining scores of EMMPRIN and matriptase. Higher EMMPRIN and matriptase immunostaining scores in HCCs also correlated significantly with tumour grading and TNM stages. Conclusions: Our findings demonstrate for the first time that EMMPRIN and matriptase are overexpressed in HCC. These may be novel biomarkers for the diagnosis and treatment of HCC.",
keywords = "CD147, EMMPRIN, Hepatocellular carcinoma, Matriptase, Serine proteinase",
author = "Tsai, {W. C.} and Chao, {Y. C.} and Lee, {W. H.} and A. Chen and Sheu, {L. F.} and Jin, {J. S.}",
year = "2006",
month = "10",
doi = "10.1111/j.1365-2559.2006.02516.x",
language = "English",
volume = "49",
pages = "388--395",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma

T2 - Tissue microarray analysis of immunohistochemical scores with clinicopathological parameters

AU - Tsai, W. C.

AU - Chao, Y. C.

AU - Lee, W. H.

AU - Chen, A.

AU - Sheu, L. F.

AU - Jin, J. S.

PY - 2006/10

Y1 - 2006/10

N2 - Aims: To examine the expression of extracellular matrix metalloprotease inducer (EMMPRIN) and matriptase in hepatocellular carcinoma (HCC) and to correlate this with tumour progression. Methods and results: Immunohistochemical analysis of EMMPRIN and matriptase was performed on tissue microarrays of 122 cases of HCC with various histological grades and/or clinical parameters. The expression of EMMPRIN and matriptase was undetectable in normal liver parenchyma of all eight control cases. However, among the 122 HCC cases, EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm. The average immunostaining scores of EMMPRIN were 88 for grade I HCC, 195 for grade II HCC and 293 for grade III HCC. Of 85 HCC cases in 122 with detailed clinical TNM stages, the average immunostaining scores of EMMPRIN were 75 for stage T1, 177 for stage T2, 260 for stage T3 and 313 for stage T4 cases of HCC. In addition, the average immunostaining scores of matriptase were 84 for grade I HCC, 187 for grade II HCC, 302 for grade III HCC, and 72 for stage T1, 181 for stage T2, 224 for stage T3 and 284 for stage T4 cases of HCC. More advanced M and N stages of HCC were associated with higher intensity, greater percentages of tumour staining and immunostaining scores of EMMPRIN and matriptase. Higher EMMPRIN and matriptase immunostaining scores in HCCs also correlated significantly with tumour grading and TNM stages. Conclusions: Our findings demonstrate for the first time that EMMPRIN and matriptase are overexpressed in HCC. These may be novel biomarkers for the diagnosis and treatment of HCC.

AB - Aims: To examine the expression of extracellular matrix metalloprotease inducer (EMMPRIN) and matriptase in hepatocellular carcinoma (HCC) and to correlate this with tumour progression. Methods and results: Immunohistochemical analysis of EMMPRIN and matriptase was performed on tissue microarrays of 122 cases of HCC with various histological grades and/or clinical parameters. The expression of EMMPRIN and matriptase was undetectable in normal liver parenchyma of all eight control cases. However, among the 122 HCC cases, EMMPRIN and matriptase immunoreactivity was seen on the cell membrane and in the cytoplasm. The average immunostaining scores of EMMPRIN were 88 for grade I HCC, 195 for grade II HCC and 293 for grade III HCC. Of 85 HCC cases in 122 with detailed clinical TNM stages, the average immunostaining scores of EMMPRIN were 75 for stage T1, 177 for stage T2, 260 for stage T3 and 313 for stage T4 cases of HCC. In addition, the average immunostaining scores of matriptase were 84 for grade I HCC, 187 for grade II HCC, 302 for grade III HCC, and 72 for stage T1, 181 for stage T2, 224 for stage T3 and 284 for stage T4 cases of HCC. More advanced M and N stages of HCC were associated with higher intensity, greater percentages of tumour staining and immunostaining scores of EMMPRIN and matriptase. Higher EMMPRIN and matriptase immunostaining scores in HCCs also correlated significantly with tumour grading and TNM stages. Conclusions: Our findings demonstrate for the first time that EMMPRIN and matriptase are overexpressed in HCC. These may be novel biomarkers for the diagnosis and treatment of HCC.

KW - CD147

KW - EMMPRIN

KW - Hepatocellular carcinoma

KW - Matriptase

KW - Serine proteinase

UR - http://www.scopus.com/inward/record.url?scp=33748745740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748745740&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2006.02516.x

DO - 10.1111/j.1365-2559.2006.02516.x

M3 - Article

C2 - 16978202

AN - SCOPUS:33748745740

VL - 49

SP - 388

EP - 395

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 4

ER -